Vivitrol Articles
Alkermes shrugs off Bydureon and focuses on pipeline, company reveals in interview with EP Vantage
15 November 2010
US FDA approves Alkermes’ Vivitrol to treat opioid-dependent patients and orphan status for PharmaLink’s Nefecon
13 October 2010
US FDA advisories say no to Arena/Eisai’s obesity drug lorcaserin; back new use for Alkermes’ Vivitrol
17 September 2010
Alkermes completes Ph IIIb Vivitrol enrollment
22 April 2009
Stock Commentary - New York week to Feb 16, 2009
23 February 2009
Alkermes/J&J's Vivitrol approved in Russia
11 August 2008
Reliant sale boosts Alkermes 3rd-qtr EPS
18 February 2008
Cilag licenses Alkermes
14 January 2008
Alkermes sees fiscal 1st-qtr net income of $8.7M
13 August 2007
Alkermes submits Vivitrol MAA in UK and Germany
9 April 2007
Alkermes reports $3M 4th-qtr 2006 net income
19 February 2007
FDA approves Vivitrol for alcohol dependency
24 April 2006
Stock Commentary - New York week to Jan 9
9 January 2006
Vivitrol gains FDA approvable letter
9 January 2006
Showing 1-17 of 17 articles
- 1
- US FDA advisory panel backs approval of Merck & Co's suvorexant, but only at lower doses
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- Italy's pharma market slump set to continue, warns GlobalData
